Condensed Consolidated Financial Statement Detail (Tables)

9 Months Ended

Sep. 30, 2013

Condensed Consolidated Financial Statement Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Common stock options and restricted stock units		6,825		5,730		6,017		5,788
Warrants for common stock		15,970		16,626		16,106		12,942
Total		22,795		22,356		22,123		18,730

Accrued liabilities

Accrued liabilities consisted of the following at September 30, 2013 and December 31, 2012 (in thousands):

	September 30,2013		December 31,2012
Accrued management incentive compensation	$	3,112	$	3,978
Accrued payroll and other benefits		2,708		2,461
Accrued clinical trial costs		500		4,702
Other		1,696		1,904
Total	$	8,016	$	13,045